Saturday 17 October 2026
Export ESLA’s income statement to Excel — free account
Estrella Immunopharma, Inc.
ESLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 329.2%, each against the same quarter a year earlier.
0.43
0.11
−20.37%
Follow ESLA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 9.72 | 9.90 | 1.02 | 0.63 | 0.73 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 10.06 | 10.50 | 33.00 | 3.23 | 3.15 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 3 | 3 | — | 3 | 8 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | 0 | (1) | (11) | (4) | (13) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | — | 0 | (1) | (11) | (4) | (13) | |||||
| Depreciation | — | — | — | — | — | 0 | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | (0.05) | (0.70) | (36.35) | (0.12) | (0.35) | |||||
| Cash flow | — | — | — | — | — | (0.27) | (0.74) | (4.37) | (0.09) | (0.05) | |||||
| Capex | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | — | — | (0.27) | (0.74) | (4.37) | (0.09) | (0.05) | |||||
| Book value | — | — | — | — | — | (0.85) | (1.59) | (22.06) | 0.00 | (0.28) | |||||
| Shares, m | — | — | — | — | — | 1 | 1 | 0 | 37 | 37 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | 0 | (1) | (1) | (3) | (2) | ||||
| Capex | — | — | — | — | — | 0 | — | — | — | — | |||||
| Free cash flow | — | — | — | — | — | 0 | (1) | (1) | (3) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | (1) | (7) | (1) | (12) | ||||
| Total debt | — | — | — | — | — | — | 0 | — | — | — | |||||
| Net debt | — | — | — | — | — | 0 | 0 | (2) | (1) | (1) | |||||
| Shareholders’ equity | — | — | — | — | — | (1) | (2) | (7) | 0 | (10) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | (3.91) | (1.11) | (174.31) | (116.58) | (413.55) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | (8.30) | 18.87 | 158.80 | (200.44) | 255.59 | |||||
Negative figures in brackets.
Charts ten years each
Estrella Immunopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ABVC ABVC BioPharma, Inc. | $24.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $23.9M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CYAD Celyad SA | $23.8M | — (loss-making) | — (loss-making) | — | n/m | +78.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PLRZ Polyrizon Ltd. | $23.7M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| IMMP Prima BioMed Ltd | $23.7M | — (loss-making) | — | — | n/m | −589,653.13% (below 0%: shrinking) | 100.00% | (101.89%) | Compare |
| EVAX Evaxion A/S - Sponsored ADR | $23.4M | — (loss-making) | — (loss-making) | +14,590.20% (above 0%: growing) | n/m | −56.70% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ESLA Estrella Immunopharma, Inc. | $23.3M | — (loss-making) | — | — | n/m | −329.19% (below 0%: shrinking) | — | 0.00% | |
| CNTX Context Therapeutics Inc. | $22.1M | — (loss-making) | — | — | n/m | −20.61% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| QNTM Quantum Biopharma Ltd. | $21.9M | — (loss-making) | — (loss-making) | — | n/m | +5.88% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $23.7M | — | — | +14,590.20% | — | −7.37% | 100.00% | 0.00% |
Estrella Immunopharma, Inc. (ESLA) key facts
- Estrella Immunopharma, Inc. (ESLA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ESLA traded at $0.43, a market capitalization of $23.3 million.
- Return on equity was 255.6% and debt-to-equity 0.00.